Vanda Pharmaceuticals | VNDA - Cost Of Sales


Vanda Pharmaceuticals reported $198.77M in Cost of Sales for its fiscal quarter ending in December of 2024.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 24.79M 1.43M Mar/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Akebia Therapeutics USD 10.34M 441K Dec/2025
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
Anika Therapeutics USD 11.44M 797K Dec/2025
AstraZeneca USD -204M 3.48B Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Eli Lilly USD 3.58B 205M Mar/2026
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
Halozyme Therapeutics USD 108.75M 6.6M Mar/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Insmed USD 49.5M 3.34M Mar/2026
J&J USD 8.07B 103M Mar/2026
Lexicon Pharmaceuticals USD 201K 191K Dec/2025
Ligand Pharmaceuticals USD 11.37M 8.38M Mar/2026
Merck USD 2.94B 380M Mar/2026
Minerva Neurosciences 386K 31K Jun/2024
Moderna USD 955M 503M Mar/2026
Novartis USD 3.54B 7M Dec/2025
Pfizer USD 4.59B 1.7B Mar/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sanofi EUR 3.67B 621M Mar/2026
Takeda JPY 560.54B 159.39B Mar/2026
Teva Pharmaceutical Industries USD 2.01B 46M Mar/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Veracyte USD 38.49M 794K Mar/2026